Endo International plc Announces Pricing of Private Offering Of Senior Notes

 Endo International plc Announces Pricing of Private Offering Of Senior Notes

  PR Newswire

  DUBLIN, June 26, 2014

DUBLIN, June 26, 2014 /PRNewswire/ --Endo International plc (NASDAQ: ENDP)
(TSX: ENL) ("Endo") today announced that Endo Finance LLC and Endo Finco Inc.,
its wholly-owned subsidiaries, priced $750 million aggregate principal amount
of 5.375% senior notes due January 2023 at an issue price of $1,000 per $1,000
principal amount in connection with their previously announced private
offering. The notes will be unsecured, unsubordinated obligations of Endo
Finance LLC and Endo Finco Inc. and will be guaranteed by Endo Limited, a
wholly-owned subsidiary of Endo, and certain of Endo Limited's direct and
indirect subsidiaries.

Endo intends to use the net proceeds from the offering for general corporate
purposes, which may include acquisitions, including the acquisition of Dava
Pharmaceuticals, Inc.

The notes and the related guarantees have not been registered under the
Securities Act of 1933, as amended, or any applicable state or foreign
securities laws, and will be offered only to qualified institutional buyers in
reliance on Rule 144A, and outside the United States in compliance with
Regulation S under the Securities Act. Unless so registered, the notes and the
related guarantees may not be offered or sold in the United States except
pursuant to an exemption from the registration requirements of the Securities
Act and applicable state securities laws. This press release will not
constitute an offer to sell or a solicitation of an offer to buy any notes or
any other securities.

Forward-Looking Statements This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and Canadian securities legislation. These forward-looking statements
include the following: Endo's intention to offer $[750] million in aggregate
principal amount of notes and Endo's intention regarding the use of the net
proceeds of the offering. Statements including words such as "believes,"
"expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look
forward," "intend," "guidance," "future" or similar expressions are
forward-looking statements. Because these statements reflect our current
views, expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties. Although Endo
believes that these forward-looking statements and information are based upon
reasonable assumptions and expectations, readers should not place undue
reliance on them, or any other forward looking statements or information in
this news release. Investors should note that many factors, as more fully
described in the documents filed by Endo with securities regulators in the
United States and Canada including under the caption "Risk Factors" in Endo
Health Solutions Inc.'s ("EHSI") Form 10-K, and Endo's Form 10-Q and Form 8-K
filings, as applicable, with the Securities and Exchange Commission and with
securities regulators in Canada on the System for Electronic Document Analysis
and Retrieval ("SEDAR") and as otherwise enumerated herein or therein, could
affect Endo's future financial results and could cause Endo's actual results
to differ materially from those expressed in forward-looking statements
contained in EHSI's Annual Report on Form 10-K. The forward-looking statements
in this press release are qualified by these risk factors. These are factors
that, individually or in the aggregate, could cause our actual results to
differ materially from expected and historical results. Endo assumes no
obligation to publicly update any forward-looking statements, whether as a
result of new information, future developments or otherwise, except as may be
required under applicable securities law.

Contact: Investors/Media: Blaine Davis, +1 (484) 216-7158, +353-1-669-6635, or
Investors: Jonathan Neely, +1 (484) 216-6645, Media: Brian O'Donnell, +1 (484)
Press spacebar to pause and continue. Press esc to stop.